Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7429-01 first-in-human dose escalation in advanced solid tumors
jRCT2041260054Phase 1Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-7429 in Nonhematologic neoplasms, sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability and Safety. Started Jun 2026; status: recruiting.
02
Drugs
ONO-7429
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2041260054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260054.